GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
Man lost 54 Kgs in 6 months with MGB procedure
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Previously, the use of the drug was limited to patients requiring hospitalization
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Subscribe To Our Newsletter & Stay Updated
